DavidARinaldiMD

PubMed

• 2 citations
  A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer
  Paulo M. Hoff, Scott Kopetz, Matthew B. Thomas, A. Langleben, D. Rinaldi, L. Anthony, Robert A. Wolff, Yvonne Lassere, James L. Abbruzzese> ;British Journal of Cancer. 2008 Sep 2
• 25 citations
  Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for ...
  Suresh S. Ramalingam, Michael C. Perry, Renato V. La Rocca, David Rinaldi, Preston S. Gable, William Tester, Chandra P. Belani> ;Cancer. 2008 Aug 1
• 110 citations
  Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patient...
  Chandra P. Belani, Suresh S. Ramalingam, Michael C. Perry, Renato V. LaRocca, David Rinaldi, Preston S. Gable, William Tester> ;Journal of Clinical Oncology. 2008 Jan 20
• 19 citations
  Treatment of Elderly Non–small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomiz...
  Suresh Ramalingam, John Barstis, Michael C. Perry, Renato V. La Rocca, Sreenivasa Nattam, David Rinaldi, Ray Clark, Glenn Mills, Chandra P. Belani> ;Journal of Thoracic Oncology. 2006 Mar 1
• 6 citations
  Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial.
  John D. Hainsworth, Denise A. Yardley, David R. Spigel, A. A. Meluch, David Rinaldi, Frederick M. Schnell, F. Anthony Greco> ;Cancer Investigation. 2006 Jan 1
• Outcome of elderly (≥70 years) non-small cell lung cancer (NSCLC) patients on a multicenter, phase III randomized trial comparing weekly vs. standard schedules of pacl...
  Ramalingam S, Perry MC, Larocca RV, Rinaldi DA, Gable P, Tester WJ, Belani CP> ;J. Clin. Oncol.. 2005-06-01
• Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small cell lung cancer (NSCLC) patients.
  Belani CP, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ> ;J. Clin. Oncol.. 2005-06-01
• An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer.
  Fields ALA, Rinaldi DA, Henderson CA, Germond CJ, Chu L, Brill KJ, Leopold LH, Berger MS> ;J. Clin. Oncol.. 2005-06-01
• A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks,...
  Belani CP, Larocca RV, Rinaldi DA, Tester WJ, Gable PS, Perry MC> ;J. Clin. Oncol.. 2004-07-15
• A phase I trial of weekly gemcitabine (GEM), administered as a constant dose-rate infusion, and docetaxel (DOC) in patients with advanced solid tumors (LOA-8).
  Rinaldi DA, Lormand NA, Rainey JM, Brierre JE, Cole JL, Roden KB> ;J. Clin. Oncol.. 2004-07-15
• Irinotecan, carboplatin, and imatinib in extensive stage small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network.
  Raefsky EL, Hainsworth JD, Rinaldi D, Schreeder M, Spigel DR, Burris HA, Yardley DA, Thompson DS, Greco FA> ;J. Clin. Oncol.. 2004-07-15
• 20 citations
  Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
  David J. Vaughn, Archie W. Brown, W. Graydon Harker, Sang Huh, Lance Miller, David Rinaldi, Fairooz Kabbinavar> ;Cancer. 2004 Feb 15
• 150 citations
  Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Obse...
  Chandra P. Belani, John Barstis, Michael C. Perry, Renato V. La Rocca, Sreenivasa Nattam, David Rinaldi, Ray Clark, Glenn Mills> ;Journal of Clinical Oncology. 2003 Aug 1
• 93 citations
  Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Ca...
  A. A. Meluch, F. Anthony Greco, J. R. Gray, M. Thomas, Valerie M. Sutton, J. Lucian Davis, L A Kalman, Don W. Shaffer, Kathleen Yost, David Rinaldi, John D. Hainsworth> ;Cancer Journal. 2003 Jul 1
• 226 citations
  Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer
  Charles S. Fuchs, Melvin R. Moore, Graydon Harker, Luis Villa, David Rinaldi, J. Randolph Hecht> ;Journal of Clinical Oncology. 2003 Mar 1
• 3 citations
  Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
  David A. Rinaldi, Nancy A. Lormand, Joseph E. Brierre, James L. Cole, M. Patrick Stagg, M. Felicia Fontenot, Eric J. Buller, John M. Rainey> ;American Journal of Clinical Oncology. 2002 Oct 1
• 15 citations
  A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma
  David A. Rinaldi, Nancy A. Lormand, Joseph E. Brierre, James L. Cole, Brian C. Barnes, Glen Mills, Siva Yadlapati, M. Felicia Fontenot, Eric J. Buller, John M. Rainey> ;Cancer. 2002 Sep 15
• 36 citations
  Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
  Mace L. Rothenberg, J. G. Kuhn, L. J. Schaaf, G. I. Rodriguez, S. G. Eckhardt, Miguel A. Villalona-Calero, David Rinaldi, Lisa A. Hammond, Stephanie Hodges, Abhishek S...> ;Annals of Oncology. 2001 Nov 1
• 7 citations
  Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Resear...
  F. Anthony Greco, Howard A. Burris, J. R. Gray, Eric L. Raefsky, Charles Dobbs, Steven W. Smith, David Rinaldi, Lisa H. Morrissey, Joan B. Erland, Sharlene Litchy, Joh...> ;Cancer. 2001 Oct 15
• 5 citations
  A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
  David A. Rinaldi, Nancy A. Lormand, Joseph E. Brierre, James L. Cole, Stagg Mp, Fontenot Mf, Eric J. Buller, John M. Rainey> ;American Journal of Clinical Oncology. 2000 Feb 1
• 153 citations
  A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
  David Rinaldi, John G. Kuhn, Howard A. Burris, F. Andrew Dorr, Gladys Rodriguez, S. Gail Eckhardt, Suzanne F. Jones, James R. Woodworth, Sharyn D. Baker, Connie Langle...> ;Cancer Chemotherapy and Pharmacology. 1999 Jan 1
• 102 citations
  Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
  Lisa A. Hammond, John R. Eckardt, Sharyn D. Baker, S. Gail Eckhardt, Margaret Dugan, Kelly Forral, Pascale Reidenberg, Paul Statkevich, Geoffrey R. Weiss, David Rinald...> ;Journal of Clinical Oncology. 1999 Aug 1
• 35 citations
  A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia.
  Manuel Hidalgo, D A Rinaldi, G Medina, T Griffin, J Turner, D D Von Hoff> ;Anti-Cancer Drugs. 1999 Apr 1
• 30 citations
  Phase II trial of docetaxel for cholangiocarcinoma.
  Richard Pazdur, Melanie Royce, Gladys Rodriguez, David Rinaldi, Yehuda Z. Patt, Paulo M. Hoff, Howard A. Burris> ;American Journal of Clinical Oncology. 1999 Feb 1
• 66 citations
  Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
  M. L. Rothenberg, A. Sharma, Geoffrey R. Weiss, Miguel A. Villalona-Calero, J. R. Eckardt, C. Aylesworth, M. A. Kraynak, David Rinaldi, Gladys Rodriguez, H. A. Burris,...> ;Annals of Oncology. 1998 Jul 1
• Join now to see all